艾伯维（AbbVie）旗下艾尔建美学（Allergan Aesthetics）今日正式对外宣告，其针对保妥适®美容（Botox® Cosmetic）用于改善咬肌突出问题的补充生物制剂许可申请（sBLA），已成功获得美国食品药品监督管理局（FDA）的受理。这一进展标志着该产品在拓展适应症领域迈出了关键一步，有望为相关需求人群提供新的治疗选择。
艾伯维（AbbVie）旗下艾尔建美学（Allergan Aesthetics）今日正式对外宣告，其针对保妥适®美容（Botox® Cosmetic）用于改善咬肌突出问题的补充生物制剂许可申请（sBLA），已成功获得美国食品药品监督管理局（FDA）的受理。这一进展标志着该产品在拓展适应症领域迈出了关键一步，有望为相关需求人群提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.